IP Verse

Process For Producing A Tablet Comprising Glp-1 Peptides

Patent No. EP4025192 (titled "Process For Producing A Tablet Comprising Glp-1 Peptides") was filed by Novo Nordisk on Sep 2, 2020. The application was issued on Dec 3, 2025.

Patent Summary

Patent Family

Patent family tree
Statuses, jurisdictions and citation links are shared on request.

Patent Oppositions (5)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
GALENICUM HEALTH SLUSep 3, 2026GALENICUM HEALTH SLU
GALENICUM HEALTH SLU ZHEJIANG HUAHAI PHARMACEUTICALSep 3, 2026GALENICUM HEALTH SLU
ZBM PATENTSSep 3, 2026ZBM PATENTS ZEA
CMS CAMERON MCKENNA NABARRO OLSWANGSep 2, 2026CMS CAMERON MCKENNA NABARRO OLSWANG
STRAWMANSep 2, 2026HOFFMANN EITLE

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

EP4025192

NOVO NORDISK
Application Number
EP20764666A
Filing Date
Sep 2, 2020
Status
Granted And Under Opposition
Oct 31, 2025
Publication Date
Dec 3, 2025
External Links
Slate, Register , Google Patents